LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LLY

936.53

+0.86%↑

JNJ

186.34

-0.01%↓

UNH

321.47

-2%↓

NVS

126.4

+0.75%↑

ABT

124.91

+0.22%↑

LivaNova PLC

Затворен

49.59 -2.19

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

48.7

Максимум

51.38

Ключови измерители

By Trading Economics

Приходи

354M

27M

Продажби

36M

353M

P/E

Средно за сектора

31.716

77.256

Марж на печалбата

7.705

Служители

2,900

EBITDA

340M

54M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+29.17% upside

Пазарни показатели

By TradingEconomics

Пазарна капитализация

539M

2.9B

Предишно отваряне

51.78

Предишно затваряне

49.59

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

LivaNova PLC Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.11.2025 г., 23:51 ч. UTC

Печалби

CoreCivic Cuts Fiscal Year Guidance Amid Efforts to Launch New Detention Facilities

5.11.2025 г., 23:10 ч. UTC

Печалби

DBS Third Quarter Net Dips 2.0%

5.11.2025 г., 22:55 ч. UTC

Печалби

Arm Holdings 2Q Profit Climbs on Record Demand

5.11.2025 г., 22:23 ч. UTC

Печалби

NAB's Annual Profit Falls 2.9% Amid Higher Costs, Credit Impairments -- Update

5.11.2025 г., 23:52 ч. UTC

Печалби

United Overseas Bank 3Q Net Interest Income S$2.265B Vs. $2.46B >U11.SG

5.11.2025 г., 23:49 ч. UTC

Печалби

United Overseas Bank 3Q Total Income S$3.40B Vs. S$3.83B >U11.SG

5.11.2025 г., 23:49 ч. UTC

Печалби

United Overseas Bank 3Q Net S$443M Vs. Net S$1.61B >U11.SG

5.11.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Rise on Weaker Yen, U.S. Tech Rebound -- Market Talk

5.11.2025 г., 23:42 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Reduced Odds of Fed Rate-Cut -- Market Talk

5.11.2025 г., 23:12 ч. UTC

Печалби

Nutrien 3Q Adj EPS 97c >NTR.T

5.11.2025 г., 23:11 ч. UTC

Печалби

Nutrien: Initiating Review of Strategic Alternatives for Phosphate Business >NTR.T

5.11.2025 г., 23:10 ч. UTC

Печалби

Nutrien 3Q Sales $6.01B >NTR.T

5.11.2025 г., 23:10 ч. UTC

Пазарно говорене
Печалби

AppLovin Says Conversion Rate Is Biggest Growth Lever -- Market Talk

5.11.2025 г., 23:10 ч. UTC

Печалби

Nutrien 3Q EPS 96c >NTR.T

5.11.2025 г., 23:04 ч. UTC

Печалби

Qualcomm Stock Slides After Earnings Beat -- Barrons.com

5.11.2025 г., 23:03 ч. UTC

Пазарно говорене

Macklem: Canada's Regulatory Overlap Turns Off Foreign Investors -- Market Talk

5.11.2025 г., 22:55 ч. UTC

Пазарно говорене

Macklem Says Inflation and Productivity Are Intertwined -- Market Talk

5.11.2025 г., 22:55 ч. UTC

Печалби

AppLovin Reports Strong Earnings. The Stock Is Up. -- Barrons.com

5.11.2025 г., 22:51 ч. UTC

Печалби

DBS 3Q Total Income S$5.93B, Up 3% on Year >D05.SG

5.11.2025 г., 22:50 ч. UTC

Печалби

DBS 3Q Net S$2.95B, Down 2.0% on Year >D05.SG

5.11.2025 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Preps Improved Offer in Metsera Bidding War -- Update

5.11.2025 г., 22:43 ч. UTC

Пазарно говорене
Печалби

NAB's Flat Dividend Disappoints Bears at Jarden -- Market Talk

5.11.2025 г., 22:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

5.11.2025 г., 22:36 ч. UTC

Пазарно говорене

Macklem Warns Structural Adjustment Means Slow Canadian Growth -- Market Talk

5.11.2025 г., 22:20 ч. UTC

Пазарно говорене

Bank of Canada Says Budget Plan Identifies Economy's Biggest Weakness -- Market Talk

5.11.2025 г., 22:12 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Will Take Action to Preserve Rights Under Previously-Signed Agreement >PFE

5.11.2025 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

Pfizer: Confident in Merits of Claims, Belief Metsera Has Acted in Breach of Contractual Obligations >PFE

5.11.2025 г., 22:11 ч. UTC

Придобивния, сливания и поглъщания

Pfizer Responds to Delaware Chancery Court Ruling

5.11.2025 г., 22:01 ч. UTC

Печалби

Great-West Lifeco 3Q Net C$1.16B >GWO.T

5.11.2025 г., 22:01 ч. UTC

Печалби

Great-West Lifeco 3Q Adj EPS C$1.33 >GWO.T

Сравнение с други в отрасъла

Ценова промяна

LivaNova PLC Прогноза

Ценова цел

By TipRanks

29.17% нагоре

12-месечна прогноза

Среден 65.63 USD  29.17%

Висок 80 USD

Нисък 55 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за LivaNova PLC през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

6

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

36.34 / N/AПодкрепа & съпротива

Краткосрочен план

Weak Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно LivaNova PLC

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
help-icon Live chat